Skip to content

Impact of graft-versus-host disease on relapse and survival in adults with B-cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation plus post-transplant cyclophosphamide in resource-limited settings.

Sep 2026 · Transplantation and Cellular Therapy · 0 citations · 20 references
Medicine

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for B-cell acute lymphoblastic leukemia (B-cell ALL). An important mechanism for the prevention of relapse is the graft-versus-leukemia (GVL) effect, potentially at the expense of the accompanying graft-versus-host disease (GVHD), which has varying morbidity and mortality depending on its timing and grade. The association between the development of acute GVHD and chronic GVHD and a reduced incidence of relapse in B-cell ALL has been documented extensively, although conflicting results have been described in certain settings, including haploidentical HSCT followed by post-transplant cyclophosphamide (PTCy). We retrospectively examined the transplant-related outcomes of B-cell ALL adult patients undergoing HLA-matched related donor HSCT or haploidentical HSCT plus PTCy in a single center, and its association with acute and chronic GVHD. We included 43 patients with a median age of 22 years, of whom 65.1% were male. The graft source was peripheral blood stem cells in all cases. The donor source was HLA-matched related in 30.2% of cases, and haploidentical in 69.8%. Moreover, the conditioning regimen was myeloablative in 30.2% and reduced-intensity in 69.8%. Most patients underwent HSCT in first or second complete remission (44.2% each). Measurable residual disease was positive in 11.6% of patients prior to HSCT. The 2-year cumulative incidence of relapse, non-relapse mortality and overall survival (OS) were 33.3%, 7.4% and 65.5%, respectively. In a multivariable Cox-regression analysis, we found no association between acute GVHD (HR 0.94, 95% CI 0.28-3.15, p = 0.92), mild chronic GVHD (HR 0.56, 95% CI 0.06-5.23, p = 0.61) or moderate-severe chronic GVHD (HR 0.49, 95% CI 0.04-4.86, p = 0.54) and the occurrence of relapse. Also, there was no association between acute or chronic GVHD of any grade and OS. A positive MRD status showed an association with the incidence of relapse (HR 2.32, 95% CI, 0.55-9.77, p = 0.24) and OS (HR 2.17, 95% CI, 0.55-8.51, p = 0.26). In conclusion, acute and chronic GVHD were not related to differences in relapse or survival after allogeneic HSCT followed by PTCy-based GVHD prophylaxis. This underscores the importance of reappraising the role of GVHD and GVL in evolving transplant settings.

View source

Similar papers

Open access Aug 2026

Results of second allogeneic hematopoietic stem cell transplantation for graft failure after first allogeneic hematopoietic stem cell transplantation complicated by the development of macrophage activation syndrome in children with high-risk acute leukemia

A second allo-HSCT in pediatric patients with GF complicated by MAS/sHLH demonstrates acceptable engraftment and survival outcomes, remaining the only available option for long-term disease control.

P. Kozhokar, O. Yudintseva, O. Paina et al. · 0 citations
Open access Sep 2026

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.

In AML patients receiving alloHSCT with PTCy, outcomes were largely similar regardless of whether CR1 was achieved after one or two-induction courses, with relapse incidence being higher in patients requiring 2 inductions.

A. Nagler, R. Swoboda, Allain-Thibeault Ferhat et al. · 0 citations
Open access Sep 2026

Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation

Although T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) were historically regarded as different manifestations of a single disease entity driven by immature T-lymphoblast proliferation, recent advances in molecular diagnostics and cytogenetic testing have revealed inherent differe...

Jia-Yuan Guo, Liu-Qing Huang, Zi-Xuan Li et al. · 0 citations
Open access Sep 2026

Prognostic factors of acute and chronic graft-versus-host disease in pediatric patients undergoing bone marrow haploidentical transplant with post-transplantation cyclophosphamide

Objective Haploidentical hematopoietic stem cell transplantation has become an important therapeutic option for pediatric patients lacking an HLA-identical donor. This study aimed to identify clinical and transplant-related predictors of graft-versus-host disease in Tunisian children undergoing haploidentical hematopoi...

Meriem Lameri, M. ben Khaled, Eya Ghazouani et al. · 0 citations
Open access Aug 2026

Long-term outcome of a DLI-based treatment strategy in patients with relapsed AML after TCD allogeneic stem cell transplantation is hampered by GvHD and late relapse.

The 5-year overall survival of a DLI-based strategy can induce durable remission in patients with low-burden morphologic AML relapse after TCD alloSCT, even without prior cytoreduction.

J. Bergsma, E. Argiro, K. Oosterink et al. · 1 citation
Review Open access Sep 2026

Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation

A GVL Failure Framework is proposed that organizes posttransplant relapse into three biologically defined categories of immune escape, aligns matched cellular therapies with each, and overlays a separate clinical transplant-eligibility axis that sets the therapeutic goal.

Naif I. Aljohani, Ahlam Almasari, Zayed Alzahrani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.